PB94

PB94 is a novel, brain-permeable, and highly selective small molecule inhibitor of histone deacetylase 11 (HDAC11). Developed by researchers at Massachusetts General Hospital, Harvard Medical School, and Sichuan University, PB94 exhibits an IC50 of 108 nM for HDAC11, demonstrating over 39-fold selectivity over other HDAC isoforms. In preclinical studies, PB94 has shown therapeutic potential for central nervous system (CNS) disorders, including neuropathic pain and Alzheimer's disease. It effectively crosses the blood-brain barrier, reduces neuroinflammation, and alleviates mechanical and thermal pain-like behaviors in chronic constriction injury (CCI) models. Additionally, PB94 has been radiolabeled as [11C]PB94 for positron emission tomography (PET) imaging to evaluate brain uptake and pharmacokinetics in vivo.

Other names

[11C]PB94